Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.46 |
| ▸ | GAPDH | P04406 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ADH1B | P00325 | 2/20 | 0.43 |
| ▸ | ADH1C | P00326 | 2/20 | 0.43 |
| ▸ | ADH1A | P07327 | 2/20 | 0.43 |
| ▸ | ADH4 | P08319 | 2/20 | 0.43 |
| ▸ | ADH7 | P40394 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL5203374 | 0.97 | TSHR (0.48) | TRPA1DDAH1GAPDHMAPTTSHR | |
| Hexane SCHEMBL30665128 | 0.87 | TSHR (0.53) | TSHRADH1BADH1CADH1AADH4 | |
| Hexane SCHEMBL2439199 | 0.87 | — | — | |
| Butyl Alcohol SCHEMBL17673151 | 0.87 | ALDH1A1 (0.55) | TRPA1DDAH1GAPDHMAPTTSHR | |
| Hexane SCHEMBL28985132 | 0.86 | ADH1B (0.39) | TRPA1DDAH1GAPDHMAPTTSHR | |
| Heptane SCHEMBL7200232 | 0.86 | SPHK1 (0.42) | TRPA1DDAH1GAPDHMAPTTSHR | |
| 2-Heptanol SCHEMBL28641247 | 0.85 | TRPA1 (0.50) | TRPA1DDAH1GAPDHMAPTADH1B | |
| Octane SCHEMBL2485910 | 0.84 | TSHR (0.58) | TSHRADH1BADH1CADH1AADH4 | |
| Hexane SCHEMBL2521059 | 0.84 | TSHR (0.50) | TRPA1TSHRADH1BADH1CADH1A | |
| Decane SCHEMBL30414302 | 0.84 | TSHR (0.58) | TSHRADH1BADH1CADH1AADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111229188-B | Glycopeptide antibiotic functionalized magnetic composite material and preparation method and application thereof | 天津大学 | 2022-03-29 | — | — | CN | disclosed |
| EP-3116854-B1 | NEW PROCESS FOR THE PREPARATION OF HIGH PURITY PROSTAGLANDINS | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA ZRT (HU) | 2022-01-26 | — | — | EP | disclosed |
| CN-111229188-A | Glycopeptide antibiotic functionalized magnetic composite material and preparation method and application thereof | 天津大学 | 2020-06-05 | — | — | CN | disclosed |
| US-20170037002-A1 | NEW PROCESS FOR THE PREPARATION OF HIGH PURITY PROSTAGLANDINS | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. (HU) | 2017-02-09 | — | — | US | disclosed |
| EP-2535053-A1 | MITOCHONDRIAL FUNCTION IMPROVER | Kao Corporation (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-20120302513-A1 | Mitochondrial Function Improver | KAO CORPORATION (JP) | 2012-11-29 | — | — | US | disclosed |
| US-8268360-B2 | Motor function improver | KAO CORPORATION (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120052129-A1 | Motor Function Improver | KAO CORPORATION (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20070269503-A1 | Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof | IMASIGHT INC. (CA) | 2007-11-22 | — | — | US | disclosed |
| EP-0828704-A1 | METHODS OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5629447-A | Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid | WARNER-LAMBERT COMPANY (US) | 1997-05-13 | — | — | US | disclosed |
| WO-1996038405-A1 | METHODS OF MAKING (S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1989009263-A1 | MOLECULAR CLONING AND EXPRESSION OF GENES ENCODING LIPOLYTIC ENZYMES | GIST-BROCADES N.V. (NL) | 1989-10-05 | — | — | WO | disclosed |
| EP-0334462-A1 | Molecular cloning and expression of genes encoding lipolytic enzymes | GENENCOR INTERNATIONAL, INC. (US) | 1989-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037002-A1 | NEW PROCESS FOR THE PREPARATION OF HIGH PURITY PROSTAGLANDINS | PTGES3, PTGER3, PTGES | TRPA1 3781/4885DDAH1 3140/4885GAPDH 1516/4885 |
| US-20070269503-A1 | Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof | LDLR, HMGCR, CETP | TRPA1 4872/4885DDAH1 2485/4885GAPDH 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.